Alpine Woods Capital Investors LLC Has $509,000 Stake in Ionis Pharmaceuticals, Inc. (IONS)
Alpine Woods Capital Investors LLC continued to hold its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,000 shares of the company’s stock at the end of the second quarter. Alpine Woods Capital Investors LLC’s holdings in Ionis Pharmaceuticals were worth $509,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also made changes to their positions in the company. FMR LLC raised its position in shares of Ionis Pharmaceuticals by 2.1% in the first quarter. FMR LLC now owns 18,562,420 shares of the company’s stock worth $746,210,000 after buying an additional 381,975 shares during the period. Vanguard Group Inc. raised its position in shares of Ionis Pharmaceuticals by 4.3% in the first quarter. Vanguard Group Inc. now owns 9,437,796 shares of the company’s stock worth $379,399,000 after buying an additional 384,830 shares during the period. Wellington Management Group LLP raised its position in shares of Ionis Pharmaceuticals by 56.1% in the first quarter. Wellington Management Group LLP now owns 9,360,553 shares of the company’s stock worth $376,295,000 after buying an additional 3,364,621 shares during the period. BB Biotech AG raised its position in shares of Ionis Pharmaceuticals by 7.9% in the first quarter. BB Biotech AG now owns 7,461,295 shares of the company’s stock worth $299,944,000 after buying an additional 548,123 shares during the period. Finally, BlackRock Inc. raised its position in shares of Ionis Pharmaceuticals by 37,569.7% in the first quarter. BlackRock Inc. now owns 6,559,808 shares of the company’s stock worth $263,704,000 after buying an additional 6,542,394 shares during the period. Institutional investors own 89.08% of the company’s stock.
Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) opened at 47.15 on Friday. The stock’s 50 day moving average price is $51.70 and its 200 day moving average price is $47.06. The stock has a market capitalization of $5.86 billion, a P/E ratio of 226.68 and a beta of 3.14. Ionis Pharmaceuticals, Inc. has a one year low of $24.58 and a one year high of $60.01.
Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by $0.03. Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The company had revenue of $104.15 million during the quarter, compared to the consensus estimate of $93.29 million. During the same quarter in the prior year, the business earned ($0.47) earnings per share. The firm’s revenue for the quarter was up 170.7% on a year-over-year basis. On average, analysts forecast that Ionis Pharmaceuticals, Inc. will post ($0.20) EPS for the current year.
A number of research analysts have issued reports on IONS shares. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $59.00 price target for the company in a research report on Monday, July 31st. Jefferies Group LLC restated an “underperform” rating and issued a $18.00 price objective (up previously from $17.00) on shares of Ionis Pharmaceuticals in a report on Thursday, August 10th. BMO Capital Markets restated a “buy” rating and issued a $59.00 price objective on shares of Ionis Pharmaceuticals in a report on Friday, June 2nd. Sanford C. Bernstein started coverage on Ionis Pharmaceuticals in a report on Thursday, July 27th. They issued a “market perform” rating and a $57.00 price objective for the company. Finally, Cowen and Company restated a “market perform” rating on shares of Ionis Pharmaceuticals in a report on Monday, May 22nd. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the company. Ionis Pharmaceuticals has a consensus rating of “Hold” and an average price target of $48.91.
In related news, major shareholder Ionis Pharmaceuticals Inc purchased 3,125,000 shares of Ionis Pharmaceuticals stock in a transaction dated Wednesday, July 19th. The shares were acquired at an average cost of $8.00 per share, for a total transaction of $25,000,000.00. Following the transaction, the insider now directly owns 28,884,540 shares of the company’s stock, valued at $231,076,320. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP C Frank Bennett sold 10,000 shares of the firm’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $59.29, for a total value of $592,900.00. Following the completion of the transaction, the senior vice president now owns 25,041 shares in the company, valued at $1,484,680.89. The disclosure for this sale can be found here. Insiders sold a total of 54,379 shares of company stock worth $2,946,052 over the last 90 days. 1.86% of the stock is owned by corporate insiders.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Stock Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.